At the end of last year, SEKISUI DIAGNOSTICS’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site in Kent – an opening representing the company’s commitment to serve its customers with innovative process development solutions.
The investment of 1.9 million Dollars is part of a long-term investment strategy: The R&D facility aims to grow the company’s share of the Microbial Biopharma CDMO market*, with future investment expected to focus on expanding its cGMP** manufacturing capabilities – starting with additional ISO 8 clean room capacity.
The Bioprocess Innovation Centre near Maidstone, Kent, includes 250m2 of laboratory space and 134m2 of office space, more than doubling the company’s R&D laboratory space to facilitate process transfer and development.
The new facility includes dedicated and separate microbial fermentation development, protein purification, analysis and molecular biology laboratories.
SEKISUI’s Biopharma CDMO service offering is focused on expression and purification from microbial fermentation. The group’s expertise lies in the production of enzymes with its capabilities also being suitable for plasmids, antibody fragments, and other protein production.
“This investment represents our commitment to serve our customers with innovative process development solutions,” says Will Stockburn, General Manager of SEKISUI DIAGNISTICS (UK) LTD. “Over many years we have built a technical competency in enzyme production process development. The new facility will enable our team to attract more customers as the Biopharma CDMO market grows.”
* CDMO: Contract Development and Manufacturing Organization
** cGMP: Current Good Manufacturing Practice
For more information on SEKISUI’s Biopharma CDMO service, please visit: https://www.bioproduction-sekisui.com
This article could also be interesting for you:
